Weight loss injections and sleep apnoea: what the evidence says

You've been told sleep apnoea is weight-related, here's what that means in practice

Picture this: you've had the sleep study, you've got the diagnosis, and your consultant or GP has mentioned that losing weight could help. That's not a brush-off. Obstructive sleep apnoea occurs when soft tissue at the back of the throat collapses during sleep, partially or fully blocking the airway. Excess fat around the neck and upper chest increases that pressure substantially, and research consistently shows that even a 10% reduction in body weight can translate to a meaningful fall in the apnoea-hypopnoea index, the number of interrupted breathing events per hour used to grade severity.

This is why sleep apnoea sits on the list of weight-related conditions that affect eligibility for GLP-1 treatment. Under the UK licensed criteria for tirzepatide (Mounjaro) and semaglutide (Wegovy), adults with a BMI of 27 or above who have at least one qualifying condition (which includes obstructive sleep apnoea) may be eligible for assessment. The full eligibility picture depends on more than BMI alone; your prescriber looks at your health history as a whole. A common misconception worth setting aside gently: people sometimes assume these injections work on the airway itself, perhaps reducing inflammation or acting on breathing directly. They don't. The benefit comes through weight loss, significant, sustained weight loss that reduces the physical load on your upper airway over time.

That distinction matters, because it means the timeline is gradual. You're unlikely to notice improved sleep after your first few doses. The benefit builds as weight comes down over weeks and months, typically alongside your existing management such as CPAP therapy.

What the SURMOUNT-OSA trial data actually found

The evidence here is more specific than you might expect. SURMOUNT-OSA was a dedicated phase-three trial examining tirzepatide in adults with moderate-to-severe obstructive sleep apnoea and obesity, two groups, one using CPAP and one not. Over 52 weeks, participants taking tirzepatide at the maximum tolerated dose experienced substantial reductions in the apnoea-hypopnoea index alongside an average body weight reduction of around 20%, consistent with results seen across the wider SURMOUNT programme involving thousands of adults. The reductions in AHI were clinically significant across both groups. These are the strongest trial data linking a licensed UK weight-loss injection directly to sleep apnoea outcomes, and they informed how obstructive sleep apnoea is framed within the tirzepatide evidence base.

Semaglutide (Wegovy) also has supporting data through the STEP trials and related cardiovascular work, with weight loss in the 15% range in the STEP 1 study tending to correspond to improvements in weight-related comorbidities including respiratory conditions. The NHS medicines page for tirzepatide outlines the licensed indications and confirmed conditions that qualify, while NICE's appraisal of tirzepatide (TA1026) sets out the formal recommendation framework for NHS and private use. Worth checking both if you want to understand where the clinical consensus currently sits.

One practical detail: because these medicines reduce appetite significantly, some people on GLP-1 treatment find that maintaining adequate protein intake takes deliberate effort. This matters for sleep apnoea patients particularly, since muscle tone around the airway is part of the picture. Your prescriber or a dietitian can help you think about diet alongside treatment.

Starting treatment when you already use a CPAP machine

Using CPAP doesn't disqualify you. Most people who start a GLP-1 injection while managing sleep apnoea with CPAP continue using their machine, at least initially. As weight falls over months of treatment, some find their pressure settings need adjusting, something to raise with the team managing your sleep apnoea rather than changing anything yourself. Your prescriber at a regulated clinic needs to know your full medical picture, including any respiratory diagnoses and current equipment, before recommending a specific medicine.

Side effects are worth preparing for. GLP-1 injections most commonly cause gastrointestinal symptoms (nausea, changes in bowel habit, reflux, and fatigue) particularly in the early weeks or after a dose increase. These are real but usually temporary. If you experience severe, persistent abdominal pain that radiates to your back, seek medical attention promptly; the MHRA issued a specific safety communication on pancreatitis as an infrequent but serious risk with GLP-1 medicines. The MHRA Yellow Card scheme is where you or your prescriber can report any suspected side effects.

For context on how treatment costs break down and what a transparent private prescription actually includes, the treatment overview page covers the detail without surprises.

How a prescriber decides whether this is the right route for you

Sleep apnoea on its own, without excess weight as a driver, wouldn't typically make someone a candidate for GLP-1 treatment. The assessment looks at whether there's a meaningful weight component and whether reducing that weight is likely to help. Your prescriber will ask about your sleep study results if available, your current BMI, any other health conditions, and what medicines you're already taking, because GLP-1 injections can affect the absorption of oral medicines, including some that matter for cardiovascular or metabolic conditions sometimes seen alongside sleep apnoea.

People who've had weight-loss surgery in the past sometimes ask whether injections are still an option; the answer depends on the procedure and timing, and there's more detail on using injections after a gastric sleeve for those in that situation. If you're thinking about eligibility more generally, the full list of contraindications is a useful starting point before your consultation. And if you're curious about the overall process from first inquiry to treatment, how to get weight loss injections in the UK walks through exactly that. Our clinical team profiles are on the prescriber page if you'd like to know more about who reviews your assessment.

If you have obstructive sleep apnoea with a weight component and want to understand whether a licensed weight-loss injection could form part of your management, check your eligibility with a free consultation. A named prescriber reviews your details the same day, not software, not a queue.